Farrow Jeffrey S 4

What Happened
Jeffrey S. Farrow, Tarsus Pharmaceuticals' Chief Financial Officer and Chief Strategy Officer, received equity awards on March 5, 2026: 30,724 option shares (derivative awards) and 19,306 restricted stock units (RSUs). Both awards are reported at a $0.00 price on the Form 4, indicating they were granted as compensation rather than purchased or sold.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026.
• Awards: 30,724 option shares (derivative award) and 19,306 RSUs; reported price $0.00.
• Shares owned after transaction: not disclosed in this filing.
• Vesting / footnotes:
  • Options (F1): 25% of option shares vest on March 5, 2027, then 1/48th of the option shares vest monthly thereafter over 3 years, subject to continuous service.
  • RSUs (F2 & F3): Each RSU converts to one common share upon vesting; RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, subject to continuous service.
• Filing type: Grant/award (transaction code A) — not a market purchase or sale.

Context
These grants are compensation awards (options and RSUs) rather than open-market purchases or sales, so they reflect executive compensation and vesting incentives rather than an immediate change in ownership or market sentiment. The option vesting schedule includes an initial one-year cliff (25% after one year) followed by monthly vesting; RSUs vest annually over four years.